Host and pathogen factors for Clostridium difficile infection and colonization

New England Journal of Medicine

Volumn 365, Issue 18, 2011, Pages 1693-1703

  Loo, Vivian G ^a   Bourgault, Anne Marie ^c,e   Poirier, Louise ^d   Lamothe, François ^c   Michaud, Sophie ^f   Turgeon, Nathalie ^g   Toye, Baldwin ⁱ   Beaudoin, Axelle ^f   Frost, Eric H ^f   Gilca, Rodica ^e,h   Brassard, Paul ^a   Dendukuri, Nandini ^a   Béliveau, Claire ^d   Oughton, Matthew ^b   Brukner, Ivan ^b   Dascal, Andre ^b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^e INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^f CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^g LAVAL UNIVERSITY   (Canada)

^h UNIVERSITÉ LAVAL   (Canada)

ⁱ UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; GLUCOCORTICOID; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; TOXIN ANTIBODY;

ADULT; AGE; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM ISOLATION; CANADA; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DEMOGRAPHY; FECES ANALYSIS; FEMALE; GENOTYPE; HEALTH CARE; HOSPITALIZATION; HOST PATHOGEN INTERACTION; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSED FIELD GEL ELECTROPHORESIS;

EID: 80455173556     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1012413     Document Type: Article

References (31)

1. Barbut F, Corthier G, Charpak Y, et al. Prevalence and pathogenicity of Clostridium difficile in hospitalized patients. Arch Intern Med 1996;156:1449-54. (Pubitemid 26226940)
2. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis 1998;26:1027-36.
3. McDonald LC. Clostridium difficile: responding to a new threat from an old enemy. Infect Control Hosp Epidemiol 2005;26:672-5. (Pubitemid 41169733)
4. Loo VG, Poirier L, Miller M, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-9. [Erratum, N Engl J Med 2006;354:2200.] (Pubitemid 41770165)
5. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998;40:1-15. (Pubitemid 28438966)
6. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010;170:784-90.
7. Johnson S, Clabots CR, Olson MM, Linn FV, Peterson LR, Gerding DN. Nosocomial Clostridium difficile colonisation and disease. Lancet 1990;336:97-100. (Pubitemid 20222816)
8. Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding DN. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 1998;351:633-6. (Pubitemid 28098446)
9. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000;342:390-7. (Pubitemid 30084537)
10. Cohen SH, Tang YJ, Silva J Jr. Analysis of the pathogenicity locus in Clostridium difficile strains. J Infect Dis 2000;181:659-63. (Pubitemid 30131836)
11. Hammond GA, Johnson JL. The toxigenic element of Clostridium difficile strain VPI 10463. Microb Pathog 1995;19:203-13.
12. Braun V, Hundsberger T, Leukel P, Sauerborn M, von Eichel-Streiber C. Definition of the single integration site of the pathogenicity locus in Clostridium difficile. Gene 1996;181:29-38. (Pubitemid 26418243)
13. Tan KS, Wee BY, Song KP. Evidence for holin function of tcdE gene in the pathogenicity of Clostridium difficile. J Med Microbiol 2001;50:613-9.
14. Drudy D, Fanning S, Kyne L. Toxin A-negative, toxin B-positive Clostridium difficile. Int J Infect Dis 2007;11:5-10. (Pubitemid 44937660)
15. Lyras D, O'Connor JR, Howarth PM, et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009;458:1176-9.
16. Popoff MR, Rubin EJ, Gill MD, Boquet P. Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain. Infect Immun 1988;56:2299-306.
17. Barth H, Aktories K, Popoff MR, Stiles BG. Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins. Microbiol Mol Biol Rev 2004;68:373-402. (Pubitemid 39238275)
18. Clabots CR, Gerding SJ, Olson MM, Peterson LR, Gerding DN. Detection of asymptomatic Clostridium difficile carriage by an alcohol shock procedure. J Clin Microbiol 1989;27:2386-7. (Pubitemid 19240636)
19. Letourneur O, Ottone S, Delauzun V, Bastide M-C, Foussadier A. Molecular cloning, overexpression in Escherichia coli, and purification of 6x his-tagged C-terminal domain of Clostridium difficile toxins A and B. Protein Expr Purif 2003;31:276-85. (Pubitemid 37325577)
20. Warny M, Vaerman J-P, Avesani V, Delmee M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994;62:384-9. (Pubitemid 24033753)
21. Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res 2007;13:559-65. (Pubitemid 46225362)
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83. (Pubitemid 17055592)
23. Miller M, Gravel D, Mulvey M, et al. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 2010;50:194-201.
24. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea in hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004;171:33-8. (Pubitemid 38925116)
25. Johnson S, Gerding DN, Janoff EN. Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile. J Infect Dis 1992;166:1287-94.
26. Alfa MJ, Kabani A, Lyerly D, et al. Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000;38:2706-14. (Pubitemid 30485154)
27. Martin H, Willey B, Low DE, et al. Characterization of Clostridium difficile strains isolated from patients in Ontario, Canada, from 2004 to 2006. J Clin Microbiol 2008;46:2999-3004.
28. Leav BA, Blair B, Leney M, et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010;28:965-9.
29. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366:1079-84. (Pubitemid 41338761)
30. Merrigan MM, Sambol SP, Johnson S, Gerding DN. New approach to the management of Clostridium difficile infection: colonisation with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration. Int J Antimicrob Agents 2009;33:Suppl:S46-S50.
31. McFarland LV, Mulligan ME, Kwok R, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989;320:204-10. (Pubitemid 19034145)